資源描述：
《肝癌前體細胞snail表達與肝癌術(shù)后預(yù)后相關(guān)性研究.pdf》由會員上傳分享，免費在線閱讀，更多相關(guān)內(nèi)容在行業(yè)資料-天天文庫。
1、68肝膽外科雜志2015年2月第23卷第1期JournalofHepatobiliarySurgery，Vol，23，No．1，F(xiàn)eb．2015·基礎(chǔ)研究·肝癌前體細胞snail表達與肝癌術(shù)后預(yù)后相關(guān)性研究楊知時，劉陽，夏勇，沈鋒【摘要】目的本研究通過檢測CD44分子和Snail蛋白在HCC中的表達，探究CD44和Snail蛋白與HCC患者臨床病理因素以及術(shù)后預(yù)后的關(guān)系。方法利用免疫組化方法檢測252名肝癌術(shù)后患者癌及癌旁組織CD44和Snail蛋白的表達。結(jié)果CD44陽性表達125例，見于細胞膜和細胞漿，Snail蛋白陽性表達121例見于細胞漿和細胞核。二者陽性表達均顯著高于癌旁組織。
2、CD44和Snail蛋白共陽性表達89例，其1一，3一，5年生存率為49．4％，31．5％，24．7％，1一，3一，5年復(fù)發(fā)率為59．9％，76．6％，81．6％。COX多因素分析中，CD44和Snail共陽性表達是生存復(fù)發(fā)的獨立危險因素。結(jié)論CD44和Snail共陽性表達與肝癌的復(fù)發(fā)和侵襲性密切相關(guān)，可作為預(yù)測肝癌患者術(shù)后預(yù)后的指標(biāo)。【關(guān)鍵詞】CD44抗原；Snail蛋白；肝細胞癌；預(yù)后評估【中圖分類號】R735．7【文獻標(biāo)識碼】A【文章編號】1006-4761(2015)01-0068-05PrognosticValueofHepatpcelluarCarcinomaprogenit
3、orcellsexpressingSnailinpatientsafterHepatectomy(YANGZhi—s，rang，XIAYong，eta1．EasternHepatobiliaryHospital，SecondMilitaryMedicalUnivertity，Shanghai200438，China)【Abstract】ObjectiveToinvestigatetheprognositicsignificanceofespressionsofCD44andSnailinpatientswithhepatocel—luarcarcinoma(HCC)．MethodsDat
4、awereretrospectivelycollectedfrom252consecutivepatientswhounderwenthepatectomyforHCCbetweenJanuary2008andJune2008attheEasternHepatobiliarySurgeryHospital(EHBH)．TheexpressionsofCD44andSnailwereanalyzedbyusingS-Pimmunohistochemicaltechnique．AccordingtotheexpressionsofCD44andSnail，bothpositiveexpres
5、sionsofCD44andSnailweredefinedaspositivegroup．Theprognosticriskfactorsfortumorrecurrenceandoverallsurvival(OS)ofthetwogroupwerecompared．ResultsThepositiveexpressionofCD44waslocatedinmembranesandcytoplasma，whilethatofthatofSnailwaslocatedincytoplasmaandnucleus．TheincidenceofCD44andSnailexpressionw
6、ere49．6％and48．0％respectively．whichwerestatisticallyhigherthantheexpressionsinpara—carcinomatissues．Therewere89patientswhoseexpressionsofCD4andSnailwerebothpositive．Thecomparisionofclinicalpathologicalcharacteristicsbetweenthepositiveandnegativegroupsshowedthatthepositivegrouphadahigeralanineamino
7、transferase(AIJT)，proportionofmulipletumors，pTMNstaging，andpositiverateforMVI．Thepost—operative1一，3一，5-yearrecurrencerates49．4％，31．5％，24．7％forpositivegroupand74．8％，56．5％，44．3％fornegetivegroup．And1一，3一，5-yearsurvivalrat
